PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk

PolTREG will produce its PTG-007 therapy with blood received from patients selected by the UCC, and deliver the finished product to UCC for a payment. Patients will then be injected with the preparation – derived from their own blood – at UCC. While PTG-007 is not yet on the market, it is available in Poland … Continued

Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes

“At PolTREG, we believe that PTG-007 has the potential to prevent type-1 diabetes, freeing patients of the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease. The results of this study are an important step in that direction,” said Prof Piotr Trzonkowski, PolTREG Chief Executive Officer. Here … Continued

PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment

Green light for PolTREG to start producing next-generation T-reg cell therapies at its own pharmaceutical plant: the company just received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment. We can now manufacture engineered T-reg cells at our state-of-the-art facility, including TCR-Tregs, CAR-Tregs and antigen-specific Tregs. These products offer exciting … Continued

PolTREG received a patent in the US protecting the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered

At PolTREG, we are very excited to announce we have received a patent in the US protecting an important part of our business: the manufacturing of T-regulatory cells (T-regs) to treat Type-1 Diabetes (T1D), and ways the therapy is administered.  “The decision by the US Patent and Trademark Office (USPTO) complements our large intellectual property … Continued

PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treatedwith its Treg therapy in combination with rituximab

PolTREG has identified a promising efficacy biomarker that may facilitate monitoring the health of Type-1 diabetes patients treated with T-regulatory cells. This is described in a study, published in the prestigious magazine International Immunopharmacology. “This peer-reviewed scientific publication adds to our growing excitement about the potential of polyclonal Treg therapies,” Chief Executive Officer Piotr Trzonkowski said in … Continued

PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellulartherapies from the Chief Pharmaceutical Inspectorate in Poland.

PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellular therapies(or Advanced Therapy Medicinal Products) from the Chief Pharmaceutical Inspectorate in Poland. We can now seek permission to perform clinical trials at the site, including for diseases such as Type-1 Diabetes (T1D) and Multiple Sclerosis with our lead asset PTG-007. PolTREG has more than 17 … Continued

PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones

PolTREG S.A., a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announces it has appointed Prof. Daniel Shelly, PhD, MBA, into the role of Chief Business Development Officer as of today, to help PolTREG build the strategic, commercial, research and pharmaceutical partnerships that will enable the company to successfully commercialise … Continued

Global institutional investors and investment funds hold over 25% of PolTREG’s shares.

Major global investors continued to accumulate PolTREG shares in 2023, adding another 129,000 shares, and bringing the total to 1.27 million. Investment funds including well-known investors like TFI Allianz Polska – part of the Allianz Group – and Norges Bank Investment Management, collectively hold over 25% of PolTREG’s shares. The trust of these global investors underscores the significant commercial potential … Continued

Prof. Piotr Trzonkowski co-authors peer-reviewed article showing scientific progress in T-regautoimmune therapy

Science has gained deep understanding of T-regulatory (Treg) cells and how to use them for therapeutical purposes in auto-immune diseases. This is what three leading research institutes in Europe showed in a peer-reviewed article in Frontiers in Immunology, the world’s fifth-most cited immunology journal. Contributors were PolTREG S.A. CEO Prof. Piotr Trzonkowski, and researchers from … Continued

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

PolTREG announces it has received a Notice of Allowance from the US Patent Office covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 Diabetes (T1D), and ways the therapy is administered. The decision paves “the way for rapid, unimpeded commercialization of PolTREG’s cell therapies,” CEO Prof. Piotr Trzonkowski was quoted as saying in today’s press … Continued